Tianjin Schering Institute of Medicine

Tianjin Schering-Plough Pharmaceutical, now officially known as MSD (Tianjin) Pharmaceutical, is a prominent pharmaceutical manufacturing and research entity located in Tianjin, China. Established in 1994 as a joint venture between the American firm Schering-Plough and the Tianjin Pharmaceutical Group, the company became a subsidiary of Merck & Co. (MSD) following the global merger of the two giants in 2009. The company operates a large-scale manufacturing facility and a research arm, often referred to as the Tianjin Schering Institute of Medicine, which focuses on formulation development and local clinical support. It is a key strategic site for MSD in the Asia-Pacific region, specializing in the production of leading allergy and respiratory treatments such as Claritin and Nasonex. The facility is recognized for its adherence to international Good Manufacturing Practice (GMP) standards and its role in supplying high-quality medicines to both domestic and international markets.